R&D
Leveraging on in-house R&D platform,the Company maintains a pipeline of projects in various clinical stages,covering a wide range of fields of indication
Remain True to Our Original Aspiration –Innovation Driven
In 1996, we established production plants for API (rb-bFGF) and formulations
In 1998, the first rb-bFGF surgical product Beifuji launched in China
In 1999, the first rb-bFGF ophthalmic product Beifushu Eye Drops launched in China
In 1998, the first rb-bFGF surgical product Beifuji launched in China
In 1999, the first rb-bFGF ophthalmic product Beifushu Eye Drops launched in China
IN-HOUSE R&D PLATFORMS
Solid R&D of biologic APIs and drug products
Growth
Factor
Factor
rb-bFGF/rh-bFGF and others for the treatment of ocular surface wounds, topical wounds, nerve injuries
Antibody
mAb, bsAb, sdAb, scFv, ADC/FDC, etc.
Drug Formulation
Successfully developed eyedrops, eye gel, spray, lyophilized powder, gel
Blow-Fill-Seal
(BFS)
(BFS)
Producing preservative-free single-dose drugs in particular ocular drugs
R&D CAPABILITIES
RESEARCH/
INNOVATION CENTRES
INNOVATION CENTRES
· Provincial Enterprise Technology Centre
· Guangdong Provincial Cytokine Engineering Technology Research Centre
· Guangdong Provincial Ophthalmic Medicine Engineering Technology Research Centre
· Guangdong Province Aerosol Inhalation Formulation Engineering Technology Research Centre
· The teaching and practice base of South China University of Technology, Wenzhou Medical University and Zunyi Medical University
· National Postdoctoral Research Station
· Guangdong Provincial Cytokine Engineering Technology Research Centre
· Guangdong Provincial Ophthalmic Medicine Engineering Technology Research Centre
· Guangdong Province Aerosol Inhalation Formulation Engineering Technology Research Centre
· The teaching and practice base of South China University of Technology, Wenzhou Medical University and Zunyi Medical University
· National Postdoctoral Research Station
HONOURS & AWARDS
· Undertook National "Ninth Five-Year Plan" major scientific and technological research project
· Undertook National "Torch Plan" Project
· Undertook National "Major New Drug Creation" Project
· Owns 31 patents, including 24 invention patents, 3 utility patents, 4 design patent
· rb-bFGF eye drops was awarded one of the National Outstanding Innovation
· rb-bFGF gel was awarded one of the National Outstanding Innovation
· Honoured with the second prize of "National Scientific and Technology Progress Award" issued by the State Council in 2004 and 2018
· Undertook National "Torch Plan" Project
· Undertook National "Major New Drug Creation" Project
· Owns 31 patents, including 24 invention patents, 3 utility patents, 4 design patent
· rb-bFGF eye drops was awarded one of the National Outstanding Innovation
· rb-bFGF gel was awarded one of the National Outstanding Innovation
· Honoured with the second prize of "National Scientific and Technology Progress Award" issued by the State Council in 2004 and 2018
R&D STRATEGY
To the Future — Broad Innovation Prospects
Continued product development，Improve drug discovery
Ophthalmology: fast-follower and to identify new generation of therapeutics
Oncology: to be global stakeholder
Ophthalmology: fast-follower and to identify new generation of therapeutics
Oncology: to be global stakeholder
Research Centre (Zhuhai, PRC)
· Conduct translational research
· Undertake for NMPA registration of in-house and overseas projects
· Talent incubation: National Post-Doctoral Research Centre set up in Zhuhai
· Undertake for NMPA registration of in-house and overseas projects
· Talent incubation: National Post-Doctoral Research Centre set up in Zhuhai
Research Centre (U.S.)
· Started in Mar 2020
· Led by Dr. XUE Qi, Chief Scientific Officer of Company
· Responsible for drug discovery and early stage product development in novel therapeutics
· Led by Dr. XUE Qi, Chief Scientific Officer of Company
· Responsible for drug discovery and early stage product development in novel therapeutics